PriceTargets.com logo

TRxADE HEALTH - MEDS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.75
  • Forecasted Upside: 472.83%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.31 As of 06/8/2023 01:00 AM ET
▼ -0.01 (-3.17%)

This chart shows the closing price for MEDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TRxADE HEALTH Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDS

Analyst Price Target is $1.75
▲ +472.83% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for TRxADE HEALTH in the last 3 months. The average price target is $1.75, with a high forecast of $1.75 and a low forecast of $1.75. The average price target represents a 472.83% upside from the last price of $0.31.

This chart shows the closing price for MEDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in TRxADE HEALTH.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2023Maxim GroupLower TargetBuy$2.50 ➝ $1.75Low
3/29/2022Maxim GroupLower Target$11.00 ➝ $7.00High
7/28/2021Maxim GroupReiterated RatingBuy$11.00Low
7/27/2021Colliers SecuritiesReiterated RatingBuy$8.00Low
7/2/2021Colliers SecuritiesReiterated RatingBuy$10.00Medium
3/30/2021Colliers SecuritiesReiterated RatingBuy$10.00High
2/26/2021Maxim GroupInitiated CoverageBuyHigh
12/3/2020National SecuritiesInitiated CoverageBuy$15.00High
6/10/2020Taglich BrothersReiterated RatingSpeculative BuyHigh
4/30/2020Dougherty & CoReiterated RatingBuy$12.00Low
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/10/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

TRxADE HEALTH logo
TRxADE HEALTH, Inc. provides an online platform for pharmaceutical purchasers. It owns and operates a business-to-business web-based marketplace focused on the United States pharmaceutical industry. The firm operates a web-based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories, and services. It also provides state-licensed pharmacies and buying groups in the United States with pharmaceuticals approved by the United States Food and Drug Administration and acts as a technology consultant provider that supports their programming needs and provides research on pharmaceutical pricing and shortages in acute care and retail settings. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Read More

Today's Range

Now: $0.31
Low: $0.29
High: $0.32

50 Day Range

MA: $0.32
Low: $0.26
High: $0.41

52 Week Range

Now: $0.31
Low: $0.25
High: $1.79

Volume

66,999 shs

Average Volume

456,375 shs

Market Capitalization

$3.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of TRxADE HEALTH?

The following Wall Street analysts have issued reports on TRxADE HEALTH in the last year: Maxim Group.
View the latest analyst ratings for MEDS.

What is the current price target for TRxADE HEALTH?

1 Wall Street analysts have set twelve-month price targets for TRxADE HEALTH in the last year. Their average twelve-month price target is $1.75, suggesting a possible upside of 472.8%. Maxim Group has the highest price target set, predicting MEDS will reach $1.75 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $1.75 for TRxADE HEALTH in the next year.
View the latest price targets for MEDS.

What is the current consensus analyst rating for TRxADE HEALTH?

TRxADE HEALTH currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MEDS will outperform the market and that investors should add to their positions of TRxADE HEALTH.
View the latest ratings for MEDS.

What other companies compete with TRxADE HEALTH?

Other companies that are similar to TRxADE HEALTH include BIMI International Medical, Motus GI, Nuwellis, Baudax Bio and IMAC. Learn More about companies similar to TRxADE HEALTH.

How do I contact TRxADE HEALTH's investor relations team?

TRxADE HEALTH's physical mailing address is 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639. The company's listed phone number is (800) 261-0281 and its investor relations email address is [email protected]. The official website for TRxADE HEALTH is www.trxade.com. Learn More about contacing TRxADE HEALTH investor relations.